Nonalcoholic fatty liver disease (NAFLD) and its severe form non-alcoholic steatohepatosis (NASH) display a rapidly increasing incidence. They may progress to primary liver cancer and have become one of the commonest reason for liver transplantation. Many clinical trials have failed to show drug efficacy, because of the poor reliability in histological assessment from liver biopsies.

To tackle this challenge, Biocellvia has developed an automated quantitative assay which mesure key morphometric parameters with accuracy and precision:

• Assessement of collagen, steatosis, ballooning and fibrosis
• Exploratory endpoints